Dual GIP/GLP-1 receptor agonists: New advances for treating type-2 diabetes.

[en] Glucagon-like peptide-1 (GLP-1) receptor agonists currently occupy a privileged place in the management of type-2 diabetes (T2D). Dual glucose-dependent insulinotropic polypeptides (GIP/GLP-1) have been recently developed. Tirzepatide is the most advanced unimolecular dual GIP/GLP-1 receptor agonist to be used as once weekly subcutaneous injection in T2D and recently received approval by the European Medicines Agency. Because of the complementarity of action of the two incretins, tirzepatide showed better dose-dependent (5, 10 and 15mg) efficacy (greater reduction in HbA1c and body weight) than placebo, basal insulin or two GLP-1 analogues (dulaglutide and semaglutide) in the SURPASS program. Its cardiovascular protective effect is currently being assessed versus dulaglutide in the SURPASS-CVOT study. Finally, studies for the treatment of obesity (SURMOUNT program) and metabolic-associated fatty liver disease (MAFLD) are also ongoing. Gastrointestinal tolerance of tirzepatide appears comparable to that of GLP-1 analogues, except for higher incidence of diarrhea. Other original molecules have been built, including triple GIP/GLP-1/glucagon receptor agonists. The risk/benefit ratio will decide whether dual (or triple) receptor agonists should replace pure GLP-1 receptor agonists for the management of T2D in the near future, with a significant role in the pharmacotherapy of obesity.

Disciplines :

Endocrinology, metabolism & nutrition
Pharmacy, pharmacology & toxicology

Author, co-author :

Scheen, André ; Centre Hospitalier Universitaire de Liège - CHU > > Service de diabétologie, nutrition, maladies métaboliques ; Division of Diabetes, Nutrition and Metabolic Disorders, Department of Medicine,

Language :

English

Title :

Dual GIP/GLP-1 receptor agonists: New advances for treating type-2 diabetes.

Publication date :

10 January 2023

Journal title :

Annales d'Endocrinologie

ISSN :

0003-4266

Peer reviewed :

Peer Reviewed verified by ORBi

Commentary :

Available on ORBi :

since 24 February 2023

Statistics

Number of views

34 (1 by ULiège)

Number of downloads

0 (0 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

Bibliography

Scheen, A.J., GLP-1 receptor agonists or DPP-4 inhibitors: how to guide the clinician?. Ann Endocrinol (Paris) 74 (2013), 515–522.
Paquot, N., Scheen, A.J., Inhibiteur de la DPP-4 ou des SGLT2 après échec de la metformine seule dans le diabète de type 2. Rev Med Suisse 13 (2017), 1410–1415.
Scheen, A.J., Perspectives dans le traitement pharmacologique du diabète de type 2 pour les 10 prochaines années. Med Mal Metab 12 (2018), 174–181.
Davies, M.J., Aroda, V.R., Collins, B.S., Gabbay, R.A., Green, J., Maruthur, N.M., et al. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European association for the study of diabetes (EASD). Diabetologia 65 (2022), 1925–1966.
American Diabetes Association Professional Practice C., American Diabetes Association Professional Practice C., Draznin, B., Aroda, V.R., Bakris, G., Benson, G., et al. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2022. Diabetes Care 45 (2022), S125–S143.
Darmon, P., Bauduceau, B., Bordier, L., Detournay, B., Gourdy, P., Guerci, B., et al. Prise de position de la Société francophone du diabète (SFD) sur les stratégies d'utilisation des traitements anti-hyperglycémiants dans le diabète de type 2-2021. Med Mal Metab 15 (2021), 781–801.
Giugliano, D., Scappaticcio, L., Longo, M., Caruso, P., Maiorino, M.I., Bellastella, G., et al. GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs. Cardiovasc Diabetol, 20, 2021, 189.
Scheen, A.J., Paquot, N., Potentialiser la perte de poids avec les agonistes des récepteurs du GLP-1. Rev Med Suisse 17 (2021), 1405–1410.
Frias, J.P., Bonora, E., Nevarez Ruiz, L., Li, Y.G., Yu, Z., Milicevic, Z., et al. Efficacy and safety of dulaglutide 3.0 mg and 4.5 mg versus dulaglutide 1.5 mg in metformin-treated patients with type 2 diabetes in a randomized controlled trial (AWARD-11). Diabetes Care 44 (2021), 765–773.
Frias, J.P., Auerbach, P., Bajaj, H.S., Fukushima, Y., Lingvay, I., Macura, S., et al. Efficacy and safety of once-weekly semaglutide 2.0 mg versus 1.0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial. Lancet Diabetes Endocrinol 9 (2021), 563–574.
Scheen, A.J., GLP-1 receptor agonists: which added value when increasing the dose?. Lancet Diabetes Endocrinol 9 (2021), 546–548.
Tschop, M.H., Finan, B., Clemmensen, C., Gelfanov, V., Perez-Tilve, D., Muller, T.D., et al. Unimolecular polypharmacy for treatment of diabetes and obesity. Cell Metab 24 (2016), 51–62.
Scheen, A.J., Paquot, N., A new paradigm for treating obesity and diabetes mellitus. Nat Rev Endocrinol 11 (2015), 196–198.
Baggio, L.L., Drucker, D.J., Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease. Mol Metab, 46, 2021, 101090.
Scheen, A.J., Radermecker, R.P., Paquot, N., Focus sur le tirzépatide, un double agoniste unimoléculaire GIP-GLP-1 dans le diabète de type 2. Rev Med Suisse 18 (2022), 1539–1544.
De Block, C., Bailey, C., Wysham, C., Hemmingway, A., Allen, S.E., Peleshok, J., Tirzepatide for the treatment of adults with type 2 diabetes: an endocrine perspective. Diabetes Obes Metab 25 (2023), 3–17.
Holst, J.J., Rosenkilde, M.M., GIP as a therapeutic target in diabetes and obesity: insight from incretin co-agonists. J Clin Endocrinol Metab 105 (2020), e2710–e2716.
Holst, J.J., Treatment of type 2 diabetes and obesity on the basis of the incretin system: the 2021 banting medal for scientific achievement award lecture. Diabetes 70 (2021), 2468–2475.
Christensen, M.B., Calanna, S., Holst, J.J., Vilsboll, T., Knop, F.K., Glucose-dependent insulinotropic polypeptide: blood glucose stabilizing effects in patients with type 2 diabetes. J Clin Endocrinol Metab 99 (2014), E418–E426.
Coskun, T., Sloop, K.W., Loghin, C., Alsina-Fernandez, J., Urva, S., Bokvist, K.B., et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. Mol Metab 18 (2018), 3–14.
Urva, S., Quinlan, T., Landry, J., Martin, J., Loghin, C., Effects of renal impairment on the pharmacokinetics of the dual GIP and GLP-1 receptor agonist tirzepatide. Clin Pharmacokinet 60 (2021), 1049–1059.
Urva, S., Quinlan, T., Landry, J., Ma, X., Martin, J.A., Benson, C.T., Effects of hepatic impairment on the pharmacokinetics of the dual GIP and GLP-1 receptor agonist tirzepatide. Clin Pharmacokinet 61 (2022), 1057–1067.
Frias, J.P., Nauck, M.A., Van, J., Benson, C., Bray, R., Cui, X., et al. Efficacy and tolerability of tirzepatide, a dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes: a 12-week, randomized, double-blind, placebo-controlled study to evaluate different dose-escalation regimens. Diabetes Obes Metab 22 (2020), 938–946.
Frias, J.P., Nauck, M.A., Van, J., Kutner, M.E., Cui, X., Benson, C., et al. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. Lancet 392 (2018), 2180–2193.
Karagiannis, T., Avgerinos, I., Liakos, A., Del Prato, S., Matthews, D.R., Tsapas, A., et al. Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis. Diabetologia 65 (2022), 1251–1261.
Rosenstock, J., Wysham, C., Frias, J.P., Kaneko, S., Lee, C.J., Fernandez Lando, L., et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet 398 (2021), 143–155.
Frias, J.P., Davies, M.J., Rosenstock, J., Perez Manghi, F.C., Fernandez Lando, L., Bergman, B.K., et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med 385 (2021), 503–515.
Ludvik, B., Giorgino, F., Jodar, E., Frias, J.P., Fernandez Lando, L., Brown, K., et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet 398 (2021), 583–598.
Del Prato, S., Kahn, S.E., Pavo, I., Weerakkody, G.J., Yang, Z., Doupis, J., et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet 398 (2021), 1811–1824.
Dahl, D., Onishi, Y., Norwood, P., Huh, R., Bray, R., Patel, H., et al. Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial. JAMA 327 (2022), 534–545.
Dutta, D., Surana, V., Singla, R., Aggarwal, S., Sharma, M., Efficacy and safety of novel twincretin tirzepatide a dual GIP and GLP-1 receptor agonist in the management of type-2 diabetes: a cochrane meta-analysis. Indian J Endocrinol Metab 25 (2021), 475–489.
Yu, Y., Hu, G., Yin, S., Yang, X., Zhou, M., Jian, W., Optimal dose of tirzepatide for type 2 diabetes mellitus: a meta-analysis and trial sequential analysis. Front Cardiovasc Med, 9, 2022, 990182.
Battelino, T., Bergenstal, R.M., Rodriguez, A., Fernandez Lando, L., Bray, R., Tong, Z., et al. Efficacy of once-weekly tirzepatide versus once-daily insulin degludec on glycaemic control measured by continuous glucose monitoring in adults with type 2 diabetes (SURPASS-3 CGM): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial. Lancet Diabetes Endocrinol 10 (2022), 407–417.
Bluher, M., Ceriello, A., Davies, M., Rodbard, H., Sattar, N., Schnell, O., et al. Managing weight and glycaemic targets in people with type 2 diabetes – how far have we come?. Endocrinol Diabetes Metab, 5, 2022, e00330.
Heerspink, H.J.L., Sattar, N., Pavo, I., Haupt, A., Duffin, K.L., Yang, Z., et al. Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial. Lancet Diabetes Endocrinol, 2022 [S2213-8587(22)00243-1].
Sattar, N., McGuire, D.K., Pavo, I., Weerakkody, G.J., Nishiyama, H., Wiese, R.J., et al. Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis. Nat Med 28 (2022), 591–598.
Nauck, M.A., D'Alessio, D.A., Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction. Cardiovasc Diabetol, 21, 2022, 169.
Gerstein, H.C., Colhoun, H.M., Dagenais, G.R., Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 394 (2019), 121–130.
Scheen, A.J., Add-on value of tirzepatide versus semaglutide. Lancet Diabetes Endocrinol 10 (2022), 377–378.
Marso, S.P., Bain, S.C., Consoli, A., Eliaschewitz, F.G., Jodar, E., Leiter, L.A., et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375 (2016), 1834–1844.
Vadher, K., Patel, H., Mody, R., Levine, J.A., Hoog, M., Cheng, A.Y., et al. Efficacy of tirzepatide 5, 10 and 15 mg versus semaglutide 2 mg in patients with type 2 diabetes: an adjusted indirect treatment comparison. Diabetes Obes Metab 24 (2022), 1861–1868.
Heise, T., Mari, A., DeVries, J.H., Urva, S., Li, J., Pratt, E.J., et al. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial. Lancet Diabetes Endocrinol 10 (2022), 418–429.
Iqbal, J., Wu, H.X., Hu, N., Zhou, Y.H., Li, L., Xiao, F., et al. Effect of glucagon-like peptide-1 receptor agonists on body weight in adults with obesity without diabetes mellitus-a systematic review and meta-analysis of randomized control trials. Obes Rev, 23, 2022, e13435.
Jastreboff, A.M., Aronne, L.J., Ahmad, N.N., Wharton, S., Connery, L., Alves, B., et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med 387 (2022), 205–216.
Ghosal, S., Datta, D., Sinha, B., A meta-analysis of the effects of glucagon-like-peptide 1 receptor agonist (GLP1-RA) in nonalcoholic fatty liver disease (NAFLD) with type 2 diabetes (T2D). Sci Rep, 11, 2021, 22063.
Patel Chavez, C., Cusi, K., Kadiyala, S., The emerging role of glucagon-like peptide-1 receptor agonists for the management of NAFLD. J Clin Endocrinol Metab 107 (2022), 29–38.
Eslam, M., Sanyal, A.J., George, J., International Consensus P., MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology 158 (2020), 1999–2014.e1.
Hartman, M.L., Sanyal, A.J., Loomba, R., Wilson, J.M., Nikooienejad, A., Bray, R., et al. Effects of novel dual GIP and GLP-1 receptor agonist tirzepatide on biomarkers of nonalcoholic steatohepatitis in patients with type 2 diabetes. Diabetes Care 43 (2020), 1352–1355.
Gastaldelli, A., Cusi, K., Fernandez Lando, L., Bray, R., Brouwers, B., Rodriguez, A., Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial. Lancet Diabetes Endocrinol 10 (2022), 393–406.
Ordonez-Vazquez, A.L., Beltran-Gall, S.M., Pal, S.C., Mendez-Sanchez, N., Editorial: Treatment with dual incretin receptor agonists to maintain normal glucose levels may also maintain normal weight and control metabolic dysfunction-associated fatty liver disease (MAFLD). Med Sci Monit, 28, 2022, e938365.
Darbalaei, S., Yuliantie, E., Dai, A., Chang, R., Zhao, P., Yang, D., et al. Evaluation of biased agonism mediated by dual agonists of the GLP-1 and glucagon receptors. Biochem Pharmacol, 180, 2020, 114150.
Bossart, M., Wagner, M., Elvert, R., Evers, A., Hubschle, T., Kloeckener, T., et al. Effects on weight loss and glycemic control with SAR441255, a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist. Cell Metab 34 (2022), 59–74.e10.
Zhao, F., Zhou, Q., Cong, Z., Hang, K., Zou, X., Zhang, C., et al. Structural insights into multiplexed pharmacological actions of tirzepatide and peptide 20 at the GIP, GLP-1 or glucagon receptors. Nature Commun, 13, 2022, 1057.
Scheen AJ, Lefèbvre PJ. Glucagon, from past to present: a century of intensive research and controversies. Lancet Diabetes Endocrinol. 2022:S2213-s8587.
Scheen, A.J., Paquot, N., Lefebvre, P.J., Investigational glucagon receptor antagonists in phase I and II clinical trials for diabetes. Expert Opin Investig Drugs 26 (2017), 1373–1389.